Northern Trust Corp Boosts Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Northern Trust Corp raised its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 18.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,394,511 shares of the company's stock after acquiring an additional 371,886 shares during the quarter. Northern Trust Corp owned approximately 0.61% of Recursion Pharmaceuticals worth $16,187,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of RXRX. Farther Finance Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after buying an additional 1,353 shares during the period. Summit Investment Advisors Inc. boosted its stake in Recursion Pharmaceuticals by 7.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock worth $176,000 after acquiring an additional 1,875 shares in the last quarter. Wedmont Private Capital boosted its stake in Recursion Pharmaceuticals by 10.6% during the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company's stock worth $144,000 after acquiring an additional 2,000 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in Recursion Pharmaceuticals by 28.3% during the fourth quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company's stock worth $69,000 after acquiring an additional 2,235 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its stake in Recursion Pharmaceuticals by 43.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after acquiring an additional 2,387 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Analyst Ratings Changes

RXRX has been the topic of several research reports. Needham & Company LLC dropped their price objective on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Morgan Stanley reduced their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Leerink Partners reduced their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Finally, Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus target price of $7.60.

Recursion Pharmaceuticals Price Performance

RXRX traded up $0.31 during trading on Friday, hitting $4.56. 22,410,503 shares of the company traded hands, compared to its average volume of 13,175,070. The company has a market cap of $1.85 billion, a PE ratio of -2.98 and a beta of 0.99. The stock's 50-day simple moving average is $5.34 and its two-hundred day simple moving average is $6.59. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The business had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.39) EPS. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.